Center of Biomedical Research Excellence in Pharmaceutical Research and Innovation

药物研究与创新卓越生物医学研究中心

• 批准号: 10569658
• 负责人: Jon Scott Thorson
• 金额: $ 226.01万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-03-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10569658
• 关键词: Address; Area; Biology; Biomedical Research; Cardiovascular Diseases; Centers of Research Excellence; Chemicals; Clinical; Collaborations; Communicable Diseases; Communication; Core Facility; Development; Devices; Discipline; Disease; Education; Environment; Faculty; Fostering; Funding; Goals; Health; Infrastructure; Institution; Kentucky; Malignant Neoplasms; Mentors; Mentorship; Modeling; Molecular Medicine; Organic Synthesis; Outcome; Pharmacologic Substance; Pharmacy facility; Phase; Productivity; Research; Research Personnel; Research Project Grants; Research Support; Science; Scientist; Testing; Therapeutic; Translational Research; Translations; Universities; Validation; career development; clinical application; college; experience; faculty research; innovation; interdisciplinary collaboration; interest; multidisciplinary; pre-clinical; pre-clinical research; prevent; tool

PROJECT SUMMARY/ABSTRACT - OVERALL We propose to establish a Center of Biomedical Research Excellence (COBRE) in Pharmaceutical Research and Innovation at the University of Kentucky (UK). CPRI will serve as a comprehensive multidisciplinary center focused on translational chemical biology [the nexus of chemical biology (the application of chemical biology principles to develop validated probe/models to advance our understanding of biology) and pharmaceutical science (the application of pharmaceutical principles to advance leads/materials/devices that address unmet clinical needs)]. The COBRE will leverage and develop unique translational chemical biology research support infrastructure/expertise to facilitate junior faculty mentorship and career development, innovative biomedical research probe/tool/model/materials development and validation, and the early advancement of potential ‘translatable’ assets. Key COBRE infrastructure to be developed and implemented in Phase I includes the CPRI Administrative Core and two research support cores (the Translational Core and the Computational Core) and the COBRE will also further develop and leverage the COBRE for Molecular Medicine’s Organic Synthesis Core to support CPRI junior faculty projects/pilots. CPRI will initially support four outstanding junior investigators working in three therapeutic areas (cancer, infectious disease and cardiovascular disease). Our overarching hypothesis is that CPRI’s translational chemical biology focus presents a distinctly unique UK platform to: i) engage, integrate and mentor junior faculty from a broad range of fundamental, applied and clinical disciplines; ii) facilitate the development of new impactful probes/tools/models and advance innovative transdisciplinary research; and iii) bridge the gap between basic academic research discoveries and commercial/clinical application via education, mentorship and key support infrastructure. CPRI’s distinct focus on translational chemical biology and early translation fills a notable preclinical research gap for many of UK’s exceptional research centers strategically focused on understanding, treating and preventing the major diseases that contribute to Kentucky’s disproportionate health challenges. Anticipated COBRE outcomes include an increase in the number and diversity of UK junior faculty engaged in translational chemical biology research and better-prepared to develop and employ innovative biomedical probes/tools/models/materials, new sustainable UK translational chemical biology research support infrastructure and capabilities, an increase in the number of UK junior faculty with independent research funding, and a boost in the number potentially ‘translatable’ UK preclinical assets.

项目总结/摘要-总体 我们建议建立一个生物医学研究卓越中心（COBRE）在药物研究 在肯塔基州大学（英国）的创新。CPRI将作为一个综合性的多学科中心 专注于转化化学生物学[化学生物学的联系（化学生物学的应用 开发经验证的探针/模型的原则，以促进我们对生物学和药物的理解 科学（应用药学原理来推进电极导线/材料/器械， 临床需要）。COBRE将利用和开发独特的转化化学生物学研究支持 基础设施/专业知识，以促进初级教师辅导和职业发展，创新的生物医学 研究探针/工具/模型/材料的开发和验证，以及潜在的早期进展 “可翻译”资产第一阶段将开发和实施的关键COBRE基础设施包括CPRI 行政核心和两个研究支持核心（翻译核心和计算核心）， COBRE还将进一步开发和利用COBRE，用于分子医学的有机合成核心 支持CPRI初级教师项目/试点。CPRI最初将支持四名优秀的初级调查员 在三个治疗领域（癌症、传染病和心血管疾病）开展工作。 我们的总体假设是，CPRI的翻译化学生物学重点提出了一个明显独特的 英国平台：i）从广泛的基础，应用和指导初级教师 临床学科; ii）促进新的有影响力的探针/工具/模型的开发，并推进创新 跨学科研究;以及iii）弥合基础学术研究发现之间的差距， 通过教育、指导和关键支持基础设施实现商业/临床应用。CPRI的独特重点 翻译化学生物学和早期翻译填补了许多英国的显着临床前研究空白 卓越的研究中心战略性地专注于了解，治疗和预防主要疾病 导致了肯塔基州不成比例的健康挑战。预期的COBRE结果包括 从事转化化学生物学研究的英国初级教师的数量和多样性增加， 更好地准备开发和采用创新的生物医学探针/工具/模型/材料，新的可持续发展 英国转化化学生物学研究支持基础设施和能力，数量增加， 拥有独立研究资金的英国初级教师，以及潜在“可翻译”英国教师数量的增加 临床前资产。